Are anonymised databases truly anonymous? An introduction by Rodriguez, Aryelly
@AUKCAR
aukcar.ac.uk
PhD studentship at the 
Asthma UK Centre for Applied Research (AUKCAR):






This work is funded by CMVM/UoE. This work is carried out 





Demands from funders, regulators and/or publishers to 
share clinical trials data to help with: 
• Out of study scope questions
• Further exploratory analysis of outcomes
• Validation and transparency
• Analysis of Individual Participant Data (IPD) in meta-
analysis 
• Development of new methodologies
• Reducing costs and increase efficiency of health 
care




•The importance and significant benefits of clinical data 
sharing have been well documented by many researchers 
in such as Gøtzsche(1), Packer(2), Al-Shahi et al.(3), 




“interests of the patients must override commercial interests”(1)
“A moral imperative”(1) 
“Respect for trial participants who often run a personal and unknown risk by 
participating in trials requires that they - and therefore also the society at 
large that they represent - be seen as the ultimate owners of trial data”(1)
“National and supranational legislation is needed to make data sharing 
happen as guidelines and other voluntary agreements do not work”(1)
“Now look at the medical literature in the 21st century. We no longer publish 
our data; instead, we present truncated summaries in the hope that readers 
will believe our conclusions without  seeing the raw observations…It is no 




•“Concerns that patient confidentiality and consent may be 
breached are often cited by researchers as a reason for 
not sharing data”(4)
•“Threat of data parasites” (4)
•Presence of overly restrictive internal governance 
(timelines and quality of data) 















IPD can only be shared if it 
is fully anonymised. But it 
is hard to completely 
anonymised while 
remaining usable
Are patients at risk of 
being identified under 
the current methods / 
guidelines used for 
anonymis tion at 
CTUs? 
“The Issue” for this project 
@AUKCAR
aukcar.ac.uk
The PhD project aims and objectives are:
a. Investigate whether individual participants can be identified 
from a range of datasets that have been anonymised and 
made available for sharing
b. Identify factors that could increase the risk of re-identification 
of a dataset 
c. Develop evidence-based recommendations on 
anonymization techniques and data security
d. Further explore researchers, patients
and public perception of the sharing of clinical




A systematic literature review is currently being executed with the 
goal to investigate:
• The current trends and practices among researchers/ 
organisations regarding anonymization techniques and policies for 
data sharing
• The potential re-identification methods that can be used on 
anonymised IPD
• The strategies that are being used to protect anonymised and 
published data against  re-identification
The literature review is including academic literature, 
reviews/reports in national media (UK) and social




Data collection: A selection of datasets that have been anonymised
and made available for sharing will be obtained from the Edinburgh
Clinical Trial Unit, Asthma UK, other Clinical Trial Units registered
with UK-CRC, private sponsors such as GSK and from peer reviewed
medical journals
Analysis: All collected datasets will be crosschecked against any 
relevant re-identifying source using publicly available information 
(including study publications and web resources) to investigate 
whether any small groups or individuals can be identified.
Also, the datasets will be assessed to determine 
how usable they are for further research.  
Finally, characteristics of the datasets (e.g. size
of the study, public vs privately funded, rare vs 
common conditions) will be recorded to




Canvas academic community, patients and public opinion 
about:
• The requirement for sharing IPD, including recognition 
of possible motives for an individual or organisation to 
identify individual participants
• Strategies to protect anonymity of patients if their 
study becomes newsworthy
This would be delivered by using





Year Month Literature Review Quantitative phase Qualitative phase 
1-2 
0-10 Perform review 
Issue requests and collect 
datasets 
Identification of stakeholders 
and tool development for 
data collection 
12 Publish results 
14-22  Send out questionnaires 
24 
Collect questionnaires, hold 
focus groups and interviews 
3-4 
26-44 
36 Summarise progress 
38-46 Test datasets 
Code and Analyse responses 
48 




Characterise datasets and 
determine risk factors 
60 Generate results Generate and Publish results 
62-72 Write PhD dissertation 
 
Overall Schedule for key milestones
@AUKCAR
aukcar.ac.uk
Many thanks to my funders 
And supervisors:
Prof S Lewis (University of Edinburgh) steff.lewis@ed.ac.uk
Prof C Weir (University of Edinburgh) Christopher.Weir@ed.ac.uk 




(1) Gøtzsche PC. Why we need easy access to all data from all clinical trials and how to accomplish it. Trials. 
2011;12:249. pmid:22112900 Why we need easy access to all data from all clinical trials and how to accomplish it
(2) Packer Milton. Data sharing: lessons from Copernicus and Kepler BMJ 2016; 354 :i4911
(3)Al-Shahi, R. & Warlow, C. (2000) Using patient-identifiable data for observational research and audit. BMJ, 321 
(7268), 1031–1032.
(4) Pisani Elizabeth, Aaby Peter, Breugelmans J Gabrielle, Carr David, Groves Trish, Helinski Michelle et al. Beyond 
open data: realising the health benefits of sharing data
BMJ 2016; 355 :i5295
(5)Monica M. Bertagnolli, M.D., Oliver Sartor, M.D., Bruce A. Chabner, M.D., Mace L. Rothenberg, M.D., Sean Khozin, 
M.D., M.P.H., Charles Hugh-Jones, M.D., David M. Reese, M.D., and Martin J. Murphy, D.Med.Sc., Ph.D. Advantages 
of a Truly Open-Access Data-Sharing Model. N Engl J Med 2017; 376:1178-1181, March 23, 2017
DOI: 10.1056/NEJMsb1702054
(6) Haddow, G., Bruce, A., Sathanandam, S. and Wyatt, J. C. (2011), ‘Nothing is really safe’: a focus group study on the 
processes of anonymizing and sharing of health data for research purposes. Journal of Evaluation in Clinical Practice, 
17: 1140–1146. doi:10.1111/j.1365-2753.2010.01488.x
@AUKCAR
aukcar.ac.uk
Thank you!
Any questions?
